Fig. 2

PET/MRI of Iodine-124 distribution in vivo. a, b, d, e Mice were inoculated i.v. with RNA-lipoplexes carrying NIS- or control-RNA, with spleen- or lung-targeting properties. Six hours later, Iodine-124 was administered and uptake was imaged and quantified 3 h after injection. c Alternatively, mice were injected i.v. with RNA-lipoplexes carrying Luc-RNA and in vivo luminescence imaging of the light emitted by luciferase activity was performed 6 h after. a Coronal slices of PET/MRI fusion and volumes of interests (red) for spleen and lung are shown in representative animals. From left to right: targeting of spleen with non-coding RNA, targeting of spleen with NIS RNA, targeting of lung with non-coding RNA, targeting of lung with NIS-RNA. b Calculated organ uptake from the volumes of interests. Data are shown as mean + SD of n = 3 mice. c Representative in vivo bioluminescence images of Luc-RNA lipoplexes after targeting the spleen and lung. d Maximum intensity projections of PET images after application of lung-targeting NIS-RNA lipoplexes (right) in comparison with non-coding control (left) e Time activity curve of Iodine-124 uptake in the lung over 60 min immediately after Iodine-124 injection (6 h after administration of NIS-RNA lipoplexes targeting the lung)